Crestor vs Amlodipine: Real-World Evidence Comparison

Why These Two Drugs Are Compared

Rosuvastatin and amlodipine sit in separate pharmacologic classes and treat separate risk factors. They appear in the same conversation for one main reason: both are first-line agents in cardiometabolic risk reduction, and cardiologists frequently prescribe them together.

The comparison becomes clinically pointed when a patient presents with borderline LDL and borderline blood pressure and the clinician must decide which problem to address first, or whether to address both simultaneously. Real-world registry data from over 60,000 statin-initiators in the CPRD UK database found that 34% were also on a calcium channel blocker within 12 months of statin initiation, with amlodipine accounting for the majority of that overlap. [1]

Mechanism: How Each Drug Works

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This upregulates LDL receptors on hepatocytes, pulling LDL-C from the bloodstream. [2] Amlodipine blocks voltage-gated L-type calcium channels in vascular smooth muscle and cardiac tissue, causing arteriolar dilation and a fall in peripheral vascular resistance. [3]

Neither drug crosses into the other's primary mechanism. A statin does not lower blood pressure in any clinically meaningful way. Amlodipine does not lower LDL-C.

Why the "Switching" Question Is Usually the Wrong Frame

Asking whether to "switch" from rosuvastatin to amlodipine (or vice versa) presumes the two drugs are alternatives. They are not. If a patient is on rosuvastatin and develops uncontrolled hypertension, adding amlodipine is the standard approach, not substituting it. If the question is about discontinuing one to simplify a regimen, that decision requires documented evidence that one of the two risk factors, LDL or BP, is no longer a target, which is rare in practice.

Rosuvastatin (Crestor): Evidence Base

Rosuvastatin 5 mg to 40 mg daily is FDA-approved for hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, and slowing the progression of atherosclerosis. [4] The 20 mg and 40 mg doses achieve LDL-C reductions of approximately 52% and 55%, respectively, from baseline. [4]

JUPITER Trial: The Defining Evidence

The JUPITER trial (N=17,802) assigned adults with LDL-C <130 mg/dL but elevated high-sensitivity CRP (≥2 mg/L) to rosuvastatin 20 mg or placebo. [5] At a median follow-up of 1.9 years, rosuvastatin cut the composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001). [5]

JUPITER is especially relevant for real-world practice because it enrolled patients who would not have qualified for statin therapy under older LDL-based thresholds alone, demonstrating benefit in a population that many clinicians considered "low risk."

Dose-Dependent LDL Lowering

The FDA label for rosuvastatin specifies a starting dose of 10 to 20 mg once daily for most adults, with 40 mg reserved for patients requiring >55% LDL-C reduction. [4] The 5 mg dose is recommended as a starting point for Asian patients due to pharmacokinetic differences that result in roughly double the plasma concentration compared to other populations. [4]

Real-World Statin Adherence Data

A 2020 analysis of U.S. Medicare claims (N=118,465) found that rosuvastatin had a 12-month medication possession ratio (MPR) of 0.72, modestly higher than atorvastatin (0.69) and substantially higher than older statins like simvastatin (0.64). [6] Higher-intensity statins show greater early discontinuation due to side effects, but rosuvastatin's tolerability profile in clinical trials has been comparable to atorvastatin at equivalent potency levels. [6]

Safety: Myopathy, Liver, and Diabetes Risk

Dose-dependent myopathy is the most-cited statin adverse effect. Rhabdomyolysis incidence with rosuvastatin is approximately 0.1 per 10,000 patient-years at doses of 10 to 20 mg, rising at 40 mg. [4] The 40 mg dose is not approved for Asian patients. [4] A meta-analysis of 13 statin trials (N=91,140) found a 9% increased relative risk of new-onset type 2 diabetes with statin use overall, with higher-intensity statins carrying somewhat greater risk. [7]

Amlodipine: Evidence Base

Amlodipine 2.5 mg to 10 mg once daily is FDA-approved for hypertension and stable coronary artery disease (CAD), including vasospastic angina and chronic stable angina. [3] The 10 mg dose produces maximum antihypertensive effect. Once-daily dosing is feasible because the drug's plasma half-life is 30 to 50 hours. [3]

ASCOT-BPLA: Amlodipine vs. Atenolol in 19,257 Patients

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA, N=19,257) compared an amlodipine-based regimen (amlodipine ± perindopril) against an atenolol-based regimen (atenolol ± bendroflumethiazide) in hypertensive patients with at least three additional cardiovascular risk factors. [8] The trial was stopped early at a median 5.5 years because the amlodipine group showed a 23% reduction in fatal and non-fatal stroke (HR 0.77, 95% CI 0.66 to 0.89, P=0.0003), a 13% reduction in total cardiovascular events and procedures (P<0.0001), and 11% fewer all-cause deaths (P=0.0247). [8]

The ACC/AHA 2017 hypertension guideline cites ASCOT-BPLA among the key studies supporting dihydropyridine calcium channel blockers as first-line antihypertensives alongside thiazides, ACE inhibitors, and ARBs. [9]

ALLHAT: Confirming CCB Outcomes

The ALLHAT trial (N=33,357) compared amlodipine (a CCB), lisinopril (an ACE inhibitor), and chlorthalidone (a thiazide diuretic) against doxazosin in hypertensive adults. [10] The primary composite outcome of fatal CHD and non-fatal MI did not differ significantly between amlodipine and chlorthalidone (RR 0.98, 95% CI 0.90 to 1.07). [10] Amlodipine did produce significantly fewer combined cardiovascular disease events than lisinopril in Black participants, an important real-world subgroup finding that influences prescribing in that population. [10]

Peripheral Edema: The Most Clinically Significant ADR

Peripheral edema affects up to 10% of patients on amlodipine 10 mg in clinical trials, compared to about 2% on placebo. [3] It results from arteriolar dilation without proportionate venodilation, increasing capillary hydrostatic pressure in the lower extremities. Switching to a dihydropyridine plus a renin-angiotensin system blocker (e.g., amlodipine + olmesartan) substantially reduces edema frequency, as demonstrated in the ACCOMPLISH trial (N=11,506). [11]

Real-World BP Control Rates

A U.S. National Health and Nutrition Examination Survey (NHANES) analysis covering 2017 to 2020 found that only 43.7% of adults with hypertension had controlled blood pressure (<130/80 mmHg under the 2017 ACC/AHA threshold). [12] Among those on CCB monotherapy, amlodipine accounted for approximately 68% of prescriptions, reflecting its dominant market position in this class. [12]

Direct Comparison: Mechanism, Targets, and Outcomes

The table below organizes the key clinical dimensions side by side. Because the two drugs target entirely different physiologic pathways, "better" is the wrong word. The right question is: which risk factor is most dangerous for this specific patient right now?

| Dimension | Rosuvastatin (Crestor) | Amlodipine | |---|---|---| | Primary target | LDL-C, non-HDL-C | Systolic and diastolic BP | | Dose range | 5 to 40 mg once daily | 2.5 to 10 mg once daily | | Key trial | JUPITER (N=17,802) [5] | ASCOT-BPLA (N=19,257) [8] | | MACE reduction | 44% RRR vs. Placebo (JUPITER) | 23% stroke RRR vs. Atenolol (ASCOT-BPLA) | | Time to peak effect | 4 weeks for LDL nadir | 6 to 8 hours for BP (steady state ~7 days) | | Primary ADR | Myopathy, new-onset DM | Peripheral edema, flushing | | Renal dose adjustment | Yes (<30 mL/min: max 10 mg) | No | | Drug-drug interactions | CYP2C9 minor; watch cyclosporine, warfarin | CYP3A4 substrate; watch strong inhibitors | | Pregnancy category | Contraindicated (X) | Category C; use if benefit outweighs risk | | Generic cost (30-day) | ~$10, $25 (GoodRx) | ~$5, $15 (GoodRx) |

Both drugs carry ACC/AHA Class I recommendations in their respective domains. The 2019 ACC/AHA Primary Prevention guideline assigns statins a Class I, Level A recommendation for patients with LDL-C ≥190 mg/dL and a Class IIa recommendation for 10-year ASCVD risk ≥7.5% in patients aged 40 to 75. [13] The 2017 ACC/AHA Hypertension guideline assigns CCBs a Class I, Level A recommendation for Stage 1 or Stage 2 hypertension in non-Black adults and a Class I recommendation as preferred therapy in Black adults without CKD or heart failure. [9]

Who Should Be on Rosuvastatin vs. Amlodipine vs. Both

The clinical decision is not binary. Three distinct patient groups present regularly in practice.

Isolated Hyperlipidemia Without Hypertension

A 52-year-old with LDL-C of 165 mg/dL and a 10-year ASCVD risk of 9% but normal BP (118/74 mmHg) needs rosuvastatin, not amlodipine. Starting amlodipine in this patient provides no evidence-based benefit for LDL reduction and may cause unnecessary edema. ACC/AHA 2019 guidelines recommend initiating moderate- to high-intensity statin therapy in this scenario. [13]

Isolated Hypertension Without Dyslipidemia

A 48-year-old with BP of 148/92 mmHg and LDL-C of 88 mg/dL on a standard Western diet does not meet criteria for statin initiation under current guidelines. Amlodipine 5 mg once daily is appropriate first-line therapy. [9] Adding rosuvastatin without an indication exposes the patient to myopathy and diabetes risk with no proven benefit.

Combined Hyperlipidemia and Hypertension (Most Common Real-World Scenario)

This is the group where the "versus" framing dissolves entirely. A 61-year-old with LDL-C of 148 mg/dL, BP of 152/94 mmHg, and a 10-year ASCVD risk of 14% should be on both rosuvastatin and amlodipine. The 2019 ACC/AHA Primary Prevention guideline states: "For adults 40 to 75 years of age with an LDL-C level of 70 to 189 mg/dL without diabetes mellitus and with an estimated 10-year ASCVD risk of 7.5% to 19.9%, it is reasonable to discuss and initiate statin therapy." [13] A separate ACC/AHA statement from 2017 identifies uncontrolled hypertension as an independent ASCVD risk enhancer that does not reduce the statin indication. [9]

Adherence to both agents in combination is a real-world challenge. A 2021 analysis of 44,000 dual-therapy initiators in a U.S. Commercial claims database found that 58% remained on both drugs at 12 months, with the most common reason for discontinuation being patient self-discontinuation of the statin rather than the antihypertensive. [14]

Pharmacokinetics and Drug Interactions

Rosuvastatin Pharmacokinetics

Rosuvastatin is minimally metabolized by CYP2C9 (minor pathway). It does not undergo significant first-pass CYP3A4 metabolism, which distinguishes it from atorvastatin and simvastatin. [4] Co-administration with cyclosporine raises rosuvastatin AUC approximately 7-fold; the combination is listed as a contraindication in the FDA label. [4] Warfarin interaction is a clinical concern: rosuvastatin may increase INR, requiring closer monitoring within the first weeks of initiation or dose change. [4]

Amlodipine Pharmacokinetics

Amlodipine is a CYP3A4 substrate. Strong CYP3A4 inhibitors, including clarithromycin, ketoconazole, and ritonavir, may increase amlodipine plasma concentrations by 40 to 60%, raising hypotension risk. [3] The interaction is clinically relevant in patients with HIV on protease inhibitors who also have hypertension, a common comorbidity pattern. [3] Amlodipine's long half-life (30 to 50 hours) means that missed doses have less BP impact than with shorter-acting antihypertensives, an advantage in real-world adherence. [3]

When Both Are Prescribed Together

No direct pharmacokinetic interaction exists between rosuvastatin and amlodipine. The combination does not require dose adjustment for either drug. [4] [3] A 2018 Cochrane review of fixed-dose combination pills for cardiovascular prevention (N=3,600 across 9 trials) found that combination pills containing a statin plus an antihypertensive improved adherence by approximately 33% relative to free-combination therapy over 12 months, with no new safety signals. [15]

Switching Rosuvastatin to Amlodipine: When It May Apply

The phrase "switching Crestor to amlodipine" usually reflects one of three clinical situations, each requiring different management.

Statin Intolerance

Approximately 5 to 10% of patients on statins report muscle symptoms sufficient to prompt discontinuation. [7] When statin intolerance is confirmed, the next step is not to switch to amlodipine but to trial an alternative statin (pravastatin, fluvastatin, pitavastatin) or bempedoic acid. Amlodipine does not substitute for LDL-C lowering in a patient with statin intolerance and elevated ASCVD risk.

Polypharmacy Reduction in Elderly Patients

In frail patients aged >80 where deprescribing is clinically appropriate, a shared decision-making framework may support discontinuing the statin if life expectancy is <2 years or the LDL-based ASCVD benefit is judged marginal. This decision does not logically require "switching to amlodipine" unless a concurrent BP indication exists. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction in Older Adults recommends individualized statin deprescribing conversations for adults over 75 with no established ASCVD. [16]

New Hypertension Diagnosis While on Rosuvastatin

This is the most common real-world trigger for the "switch" question. The patient is already on rosuvastatin and gets a new hypertension diagnosis. The answer is to add amlodipine, not replace rosuvastatin with amlodipine. [9]

Real-World Safety Monitoring

Both drugs require periodic monitoring, though the targets differ substantially.

Rosuvastatin monitoring per ACC/AHA guidelines includes a fasting lipid panel 4 to 12 weeks after initiation or dose change, then every 3 to 12 months. [13] CK measurement is not recommended at baseline unless the patient has predisposing factors for myopathy (personal or family history, CKD, hypothyroidism, high-dose statin use). [13] Liver enzyme testing at baseline and at signs of hepatotoxicity is reasonable; routine periodic LFT monitoring is no longer recommended by the FDA. [4]

Amlodipine monitoring is largely clinical: BP at each visit and symptom review for edema. No laboratory monitoring is mandated in guidelines. [9] Edema that develops on amlodipine monotherapy may respond to dose reduction to 5 mg or to the addition of an ACE inhibitor or ARB, as seen in ACCOMPLISH. [11] Switching entirely to a different antihypertensive class is an option if edema is intolerable, but the BP-lowering efficacy of amlodipine 10 mg is difficult to replicate with most other agents in monotherapy.